Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00672659 |
Recruitment Status
:
Completed
First Posted
: May 6, 2008
Last Update Posted
: May 2, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The primary objective is to demonstrate whether the addition of pipamperone 5 mg twice daily (bd) to citalopram, 40 mg daily in patients suffering from MDD will improve the efficacy of citalopram 40 mg in these patients.
Secondary objectives are to demonstrate whether the addition of pipamperone 5 mg twice daily (bd) to citalopram, 40 mg daily in patients suffering from MDD:
- Will increase the rate of resolution of symptoms with citalopram 40 mg.
- Show the combined product to be safe and tolerable.
Patients are scheduled to receive study medication for eight weeks and a final follow-up check will be carried out 28 days after completing the study.
All patients will receive active citalopram from baseline and will be randomised to receive either active pipamperone or a placebo equivalent for eight weeks during which time they will attend for 6 study visits.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Depression | Drug: Citalopram + Pipamperone Drug: Citalopram | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 165 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Phase IIa Proof of Concept Study of Pipamperone/Citalopram (PipCit) Versus Citalopram in the Treatment of Major Depressive Disorder (MDD) |
Study Start Date : | February 2008 |
Actual Primary Completion Date : | January 2009 |
Actual Study Completion Date : | January 2009 |

Arm | Intervention/treatment |
---|---|
Active Comparator: 1
Citalopram, 40 mg daily in combination with Pipamperone, 5 mg twice daily (bd)
|
Drug: Citalopram + Pipamperone
Citalopram, 40 mg daily, 8 weeks Pipamperone, 5 mg twice daily, 8 weeks
|
Placebo Comparator: 2
Citalopram, 40 mg daily in combination with Placebo, dummy twice daily (bd)
|
Drug: Citalopram
Citalopram, 40 mg daily, 8 weeks Placebo, dummy, twice a day, 8 weeks
|
- Change in Montgomery-Asberg Depression Rating Scale score [ Time Frame: 8 weeks ]
- The number of patients showing evidence of onset of action defined as a 20% improvement from baseline MADRS [ Time Frame: At Weeks 1 and 2 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male and female patients
- 18-65 years inclusive
- Suffering from a moderate to severe MDD as defined by DSM IV with an existence of depressed mood and loss of interest/anhedonia for at least four weeks and no longer than six months for the current episode
- Diagnosis will be confirmed by the Mini International Neuropsychiatric Interview (MINI) version 5.0.0.
- Clinical global impression - severity scale (CGI-S) rating of at least four and a minimum Hamilton Depression Scale (HAM-D) 17 items total score of 18 at screen and baseline
- A non-psychotic state
- Where appropriate, male patients should agree to use barrier contraceptive measures (condoms) during the course of the study and for three months after the last dose of medication
Exclusion Criteria:
- Premenopausal females not using adequate contraceptive measures
- Considered by the investigator to be a significant risk of suicide or scoring 5 or more on the MADRS question 10
- Significant other psychiatric illness which would interfere with trial assessments - co-morbid generalised anxiety disorder (GAD) and panic disorder will be permitted where MDD is considered the primary diagnosis
- Significant physical illness which would interfere with trial assessments
- Reduced hepatic function
- Epilepsy
- History of cardiac dysrhythmia
- Alcohol intake above accepted UK ranges
- Recent (1 week) antidepressant (except for fluoxetine - 4 weeks and St John's Wort or MAOI's - 14 days), benzodiazepine or any other psychotropic medication ingestion including lithium or other mood stabilisers
-
Resistant depression defined as having failed to respond to
- Two previous antidepressants at an adequate dose ingested for at least 4 weeks during the current episode
- To an augmentation therapy with an atypical antipsychotic drug
- Electroconvulsive therapy (ECT) for the current episode
- Formal psychotherapy or alternative treatments for one week prior to or during the study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00672659
United Kingdom | |
CPSResearch | |
Glasgow, Scotland, United Kingdom, G20 0XA |
Study Chair: | Erik Buntinx, MD | PharmaNeuroBoost N.V. | |
Study Director: | Alan Wade, MG | CPSResearch | |
Principal Investigator: | Gordon Crawford, MD | CPSResearch |
Additional Information:
Publications of Results:
Responsible Party: | Erik Buntinx, MD, PharmaNeuroBoost N.V. |
ClinicalTrials.gov Identifier: | NCT00672659 History of Changes |
Other Study ID Numbers: |
PNB/CPS 02 2007 |
First Posted: | May 6, 2008 Key Record Dates |
Last Update Posted: | May 2, 2011 |
Last Verified: | April 2011 |
Keywords provided by PharmaNeuroBoost N.V.:
Lost of interest, Depressed Mood |
Additional relevant MeSH terms:
Depressive Disorder Depression Depressive Disorder, Major Mood Disorders Mental Disorders Behavioral Symptoms Citalopram Dexetimide Pipamperone Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Serotonin Agents |
Physiological Effects of Drugs Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Antiparkinson Agents Anti-Dyskinesia Agents Parasympatholytics Autonomic Agents Peripheral Nervous System Agents Muscarinic Antagonists Cholinergic Antagonists Cholinergic Agents Serotonin Antagonists Antipsychotic Agents Tranquilizing Agents |